Blog

Learn how recombinant antibody production uses genetic engineering to create highly specific antibodies, replacing traditional methods for therapeutic and diagnostic use.

Examine how CHO cell line development and optimized upstream processing improve therapeutic antibody production, ensuring high yields, consistent quality, and clinical efficacy.

Therapeutic antibody discovery begins with screening. Biointron applies ELISA, SPR, and AI-driven tools to identify high-affinity antibodies with precision and speed.

Antibody engineering transforms promising candidates into therapies. Biointron applies humanization, affinity maturation, and advanced design to accelerate clinical readiness.

Identifying the right antigen is the first step in therapeutic antibody development. Biointron outlines methods that guide discovery and advance drug pipelines.

Discover how antibodies regulate immune responses, maintain homeostasis, cross biological barriers, and provide passive immunity and long-term immune protection.

Single-chain variable fragments (scFvs) combine small size with strong binding. Biointron highlights their history, uses in diagnostics and therapy, and production expertise.

Antibodies neutralize pathogens, opsonize invaders, and activate complement. Biointron highlights these essential functions as the foundation for antibody drug development.

Biointron streamlines antibody production and purification, applying recombinant expression, hybridoma methods, and chromatography techniques to ensure purity and performance.

From hybridoma to recombinant platforms, Biointron leads innovations in antibody production and engineering, enabling faster, more flexible, and reliable research solutions.

Biointron celebrates the International Day of Women and Girls in Science, honoring contributions that drive antibody discovery, biotech innovation, and global progress.

Learn about bispecific antibodies (bsAbs), their history, advantages over monoclonal antibodies, and popular engineering formats like knobs-into-holes and BiTE.